The next step for the Rise For Health study researchers is to study the health benefits of frequent standing in older men and ...

Sexual and gender minority individuals still face insurance denials and cost-sharing barriers when accessing pre-exposure ...

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when ...

National registry study finds overall survival improved across the board after the introduction of immune checkpoint ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

A new study finds Medicare beneficiaries are facing higher deductibles and cost-sharing requirements following changes ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

This recent study underscores the fact that biomarkers serve not merely as statistical instruments but as insights into ...

Prefilled syringes of Imuldosa now have the lowest wholesaler acquisition cost among all branded ustekinumab biosimilars, ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...